Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway
Hoth Therapeutics (NASDAQ: HOTH) has been granted a U.S. patent for its innovative Alzheimer's treatment, HT-ALZ. This breakthrough therapy targets the Substance P/Neurokinin-1 Receptor pathway, which is important in neuroinflammation, a key factor in Alzheimer's progression. Preclinical studies have shown promising results, including reduced neuroinflammation and improved cognitive functions.
The company is now preparing for human clinical trials, with formulation of HT-ALZ currently underway. The upcoming trials will focus on demonstrating the drug's safety, tolerability, and effectiveness in addressing cognitive decline associated with Alzheimer's disease. This patent secures Hoth's intellectual property rights and strengthens its position in Alzheimer's therapy development.
Hoth Therapeutics (NASDAQ: HOTH) ha ricevuto un brevetto negli Stati Uniti per il suo innovativo trattamento per l'Alzheimer, HT-ALZ. Questa terapia rivoluzionaria mira al percorso del recettore della sostanza P/neurochinina-1, che è fondamentale nella neuroinfiammazione, un fattore chiave nella progressione dell'Alzheimer. Studi preclinici hanno mostrato risultati promettenti, tra cui la riduzione della neuroinfiammazione e il miglioramento delle funzioni cognitive.
L'azienda si sta ora preparando per prove cliniche umane, con la formulazione di HT-ALZ attualmente in fase di sviluppo. I prossimi trial si concentreranno nel dimostrare la sicurezza, la tollerabilità e l'efficacia del farmaco nel contrastare il declino cognitivo associato alla malattia di Alzheimer. Questo brevetto protegge i diritti di proprietà intellettuale di Hoth e rafforza la sua posizione nello sviluppo di terapie per l'Alzheimer.
Hoth Therapeutics (NASDAQ: HOTH) ha recibido una patente en EE.UU. para su innovador tratamiento del Alzheimer, HT-ALZ. Esta terapia revolucionaria se dirige a la vía del receptor de sustancia P/neuroquinina-1, que es importante en la neuroinflamación, un factor clave en la progresión del Alzheimer. Los estudios preclínicos han mostrado resultados prometedores, incluyendo la reducción de la neuroinflamación y la mejora de las funciones cognitivas.
La compañía se está preparando ahora para ensayos clínicos en humanos, con la formulación de HT-ALZ en desarrollo. Los próximos ensayos se centrarán en demostrar la seguridad, tolerabilidad y efectividad del medicamento para abordar el deterioro cognitivo asociado con la enfermedad de Alzheimer. Esta patente asegura los derechos de propiedad intelectual de Hoth y fortalece su posición en el desarrollo de terapias para el Alzheimer.
호스 테라퓨틱스 (NASDAQ: HOTH)는 혁신적인 알츠하이머 치료제 HT-ALZ에 대해 미국 특허를 받았습니다. 이 획기적인 치료법은 알츠하이머 진행의 주요 요소인 신경 염증과 관련이 있는 물질 P/신경키닌-1 수용체 경로를 목표로 합니다. 전임상 연구에서 신경 염증 감소 및 인지 기능 개선을 포함한 유망한 결과가 나타났습니다.
회사는 현재 HT-ALZ의 제형 개발을 진행 중이며 인간 임상 시험을 준비하고 있습니다. 다가오는 시험은 약물의 안전성, 내약성 및 효과를 입증하는 데 중점을 둘 것입니다. 이 특허는 호스의 지적 재산권을 보호하고 알츠하이머 치료 개발에서의 지위를 강화합니다.
Hoth Therapeutics (NASDAQ: HOTH) a reçu un brevet américain pour son traitement innovant de la maladie d'Alzheimer, HT-ALZ. Cette thérapie révolutionnaire cible la voie du récepteur de la substance P/neurokinine-1, qui est importante dans la neuroinflammation, un facteur clé de la progression de la maladie d'Alzheimer. Des études précliniques ont montré des résultats prometteurs, y compris une réduction de la neuroinflammation et une amélioration des fonctions cognitives.
La société se prépare maintenant pour des essais cliniques humains, la formulation de HT-ALZ étant actuellement en cours. Les prochains essais se concentreront sur la démonstration de la sécurité, de la tolérabilité et de l'efficacité du médicament pour traiter le déclin cognitif associé à la maladie d'Alzheimer. Ce brevet protège les droits de propriété intellectuelle de Hoth et renforce sa position dans le développement de thérapies pour Alzheimer.
Hoth Therapeutics (NASDAQ: HOTH) hat ein US-Patent für seine innovative Alzheimer-Behandlung HT-ALZ erhalten. Diese bahnbrechende Therapie zielt auf den Substanz P/Neurokinin-1-Rezeptor-Weg ab, der in der Neuroinflammation wichtig ist, einem Schlüsselfaktor für die Fortschreitung der Alzheimer-Krankheit. Präklinische Studien haben vielversprechende Ergebnisse gezeigt, darunter eine reduzierte Neuroinflammation und verbesserte kognitive Funktionen.
Das Unternehmen bereitet sich nun auf klinische Studien mit Menschen vor, wobei die Formulierung von HT-ALZ derzeit in der Entwicklung ist. Die bevorstehenden Studien werden sich darauf konzentrieren, die Sicherheit, Verträglichkeit und Wirksamkeit des Medikaments zur Behandlung des mit der Alzheimer-Krankheit verbundenen kognitiven Abbaus nachzuweisen. Dieses Patent sichert Hoths geistige Eigentumsrechte und stärkt seine Position in der Entwicklung von Therapien für Alzheimer.
- Granted U.S. patent for Alzheimer's treatment HT-ALZ
- Promising preclinical results showing reduced neuroinflammation and improved cognitive functions
- Preparation for human clinical trials underway
- Strengthened intellectual property position in Alzheimer's therapy development
- None.
Insights
The granting of a U.S. patent for HT-ALZ is a significant milestone for Hoth Therapeutics. This patent protection secures their intellectual property rights, potentially giving them a competitive edge in the Alzheimer's treatment market. The focus on the Substance P/Neurokinin-1 Receptor pathway is particularly intriguing, as it targets neuroinflammation, an increasingly recognized factor in Alzheimer's progression.
The preclinical results showing reduced neuroinflammation and improved cognitive functions are promising. However, it's important to note that success in preclinical studies doesn't always translate to human trials. The upcoming clinical trials will be critical in determining HT-ALZ's true potential. If the human trials can replicate the preclinical results, it could represent a significant advancement in Alzheimer's treatment.
Investors should monitor the progress of the formulation phase and subsequent clinical trials closely. Positive results could dramatically impact Hoth's market position and valuation, especially given the large and growing market for Alzheimer's treatments.
This patent grant is a crucial development for Hoth Therapeutics, significantly enhancing its market position in the competitive Alzheimer's treatment landscape. The intellectual property protection could attract potential partnerships or licensing deals, potentially boosting the company's value.
However, investors should be cautious. While the patent is promising, Hoth faces several challenges:
- Clinical trial success is not guaranteed and many Alzheimer's treatments have failed in late-stage trials.
- The company's small market cap of
$5,045,990 suggests resources, which could impact the speed and scale of clinical development. - Potential competition from larger pharmaceutical companies with more resources.
The upcoming clinical trials will be a critical inflection point for Hoth. Positive results could lead to significant upside, while negative outcomes could severely impact the stock. Investors should closely monitor trial progress and any potential partnerships or funding arrangements that could support the costly clinical development process.
HT-ALZ represents a breakthrough in Alzheimer's treatment, specifically targeting the Substance P/Neurokinin-1 Receptor pathway. This pathway is known to play a critical role in neuroinflammation, which is increasingly recognized as a driving factor in the progression of Alzheimer's disease. Preclinical studies have shown promising results, including reduced neuroinflammation and significant improvements in cognitive functions such as memory and learning.
The patent solidifies Hoth's leadership in the development of Alzheimer's therapies and paves the way for the next phase of human clinical trials. Formulation of HT-ALZ for these trials is currently underway, with the goal of advancing this promising treatment to patients as swiftly as possible.
Next Steps
As Hoth Therapeutics completes the formulation phase, the company will look to prepare clinical trials to further validate HT-ALZ's efficacy in humans. The upcoming trials will focus on demonstrating the drug's safety, tolerability, and effectiveness in slowing or reversing the cognitive decline associated with Alzheimer's disease.
Robb Knie, CEO of Hoth Therapeutics, commented, "This patent marks a significant achievement for Hoth as we progress HT-ALZ from the lab to clinical development. The preclinical data on neuroinflammation reduction and cognitive improvement offer great hope, and we are excited to take the next critical steps toward delivering a potentially life-changing therapy to Alzheimer's patients."
About HT-ALZ
HT-ALZ represents a novel approach in Alzheimer's research, focusing on the modulation of neuroinflammation, unlike many treatments that focus solely on amyloid plaques. Preclinical data has shown that HT-ALZ effectively reduces reactive astrocytes in the brain, cells that contribute to the inflammatory processes seen in Alzheimer's, leading to improved cognitive outcomes in experimental models.
For more information about Hoth Therapeutics and HT-ALZ, please visit www.hoththerapeutics.com.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-awarded-key-us-patent-for-groundbreaking-alzheimers-treatment-and-prepares-for-clinical-trials-of-ht-alz-with-formulation-now-underway-302275779.html
SOURCE Hoth Therapeutics, Inc.
FAQ
What is the new Alzheimer's treatment developed by Hoth Therapeutics (HOTH)?
What stage is Hoth Therapeutics' (HOTH) Alzheimer's treatment HT-ALZ currently in?
What were the results of the preclinical studies for Hoth Therapeutics' (HOTH) HT-ALZ?
What is the next step for Hoth Therapeutics (HOTH) in developing HT-ALZ?
